<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970251</url>
  </required_header>
  <id_info>
    <org_study_id>Si726/2018</org_study_id>
    <nct_id>NCT04970251</nct_id>
  </id_info>
  <brief_title>Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma</brief_title>
  <official_title>Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Siriraj Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Siriraj Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment&#xD;
      to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for&#xD;
      neovascular glaucoma (NVG).&#xD;
&#xD;
      Setting: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Study&#xD;
      design: Prospective interventional case series Methods: PRP and IVA (2 mg/0.05 ml) injection&#xD;
      were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture&#xD;
      lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC&#xD;
      if indicated. Best-collected visual acuity (BCVA), intraocular pressure (IOP), surgical&#xD;
      complications, and number of anti-glaucoma medications were collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on day 1st</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on day 7th</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on month 3rd</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on month 6th</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on month 12th</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on month 18th</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on month 24th</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on month 30th</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Post-operative on month 36th</time_frame>
    <description>Intraocular pressure after trabeculectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on day 1st</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on day 7th</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on month 3rd</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on month 6th</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on month 12th</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on month 18th</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on month 24th</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on month 30th</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Post-operative on month 36th</time_frame>
    <description>Visual acuity of the studied eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of medication</measure>
    <time_frame>Post-operative on month12th</time_frame>
    <description>Numbers of anti-glaucoma medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of medication</measure>
    <time_frame>Post-operative on month 24th</time_frame>
    <description>Numbers of anti-glaucoma medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of medication</measure>
    <time_frame>Post-operative on month 36th</time_frame>
    <description>Numbers of anti-glaucoma medications</description>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Intraocular Pressure</condition>
  <condition>Neovascular Glaucoma</condition>
  <condition>Vascular Endothelial Growth Factor Overexpression</condition>
  <condition>Glaucoma Secondary to Eye Inflammation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept Ophthalmic</intervention_name>
    <description>Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.</description>
    <other_name>trabeculectomy</other_name>
    <other_name>Panretinal photocoagulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients with neovascular glaucoma who presented at the Department of&#xD;
             Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,&#xD;
             Thailand during November 2018 to October 2019.&#xD;
&#xD;
          -  Aged more than 18 year-old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who received any anti-vascular endothelial growth factor treatment before&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Naris Kitnarong</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Kitnarong N, Sriyakul C, Chinwattanakul S. A Prospective Study to Evaluate Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma. Ophthalmol Ther. 2015 Jun;4(1):33-41. doi: 10.1007/s40123-015-0033-3. Epub 2015 Mar 27.</citation>
    <PMID>25812531</PMID>
  </results_reference>
  <results_reference>
    <citation>Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008 May;25(5):438-43. doi: 10.1007/s12325-008-0047-5.</citation>
    <PMID>18425438</PMID>
  </results_reference>
  <results_reference>
    <citation>Kobayashi S, Inoue M, Yamane S, Sakamaki K, Arakawa A, Kadonosono K. Long-term Outcomes After Preoperative Intravitreal Injection of Bevacizumab Before Trabeculectomy for Neovascular Glaucoma. J Glaucoma. 2016 Mar;25(3):281-4. doi: 10.1097/IJG.0000000000000211.</citation>
    <PMID>25580888</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Siriraj Hospital</investigator_affiliation>
    <investigator_full_name>Naris Kitnarong</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Centers who collect the data of neovascular Glaucoma patients who underwent intravitreal aflibercept injection, pan retinal photocoagulation and trabeculectomy with mitomycin C.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

